Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,650 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-World Data on Ramucirumab Therapy including Patients Who Experienced Two or More Systemic Treatments: A Multicenter Study.
Yasui Y, Kurosaki M, Tsuchiya K, Hayakawa Y, Hasebe C, Abe M, Ogawa C, Joko K, Ochi H, Tada T, Nakamura S, Furuta K, Kimura H, Tsuji K, Kojima Y, Akahane T, Tamada T, Uchida Y, Kondo M, Mitsuda A, Izumi N; Japanese Red Cross Liver Study Group. Yasui Y, et al. Among authors: tada t. Cancers (Basel). 2022 Jun 16;14(12):2975. doi: 10.3390/cancers14122975. Cancers (Basel). 2022. PMID: 35740647 Free PMC article.
Validation of serological models for staging and prognostication of HCC in patients from a Japanese nationwide survey.
Toyoda H, Tada T, Johnson PJ, Izumi N, Kadoya M, Kaneko S, Kokudo N, Ku Y, Kubo S, Kumada T, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kudo M; Liver Cancer Study Group of Japan. Toyoda H, et al. Among authors: tada t. J Gastroenterol. 2017 Oct;52(10):1112-1121. doi: 10.1007/s00535-017-1321-6. Epub 2017 Feb 21. J Gastroenterol. 2017. PMID: 28224228
Clinical features of hemodialysis patients treated for hepatocellular carcinoma: Comparison between resection and radiofrequency ablation.
Hiraoka A, Kumada T, Michitaka K, Toyoda H, Tada T, Takaguchi K, Tsuji K, Itobayashi E, Takizawa D, Hirooka M, Koizumi Y, Ochi H, Joko K, Kisaka Y, Shimizu Y, Tajiri K, Tani J, Taniguchi T, Toshimori A, Fujioka S; Real-Life Practice Experts For Hepatocellular Carcinoma (HCC) (RELPEC) Study Group and The HCC 48 Group (HCC experts from 48 clinics). Hiraoka A, et al. Among authors: tada t. Mol Clin Oncol. 2017 Apr;6(4):455-461. doi: 10.3892/mco.2017.1192. Epub 2017 Mar 10. Mol Clin Oncol. 2017. PMID: 28413650 Free PMC article.
Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications.
Hiraoka A, Kumada T, Kudo M, Hirooka M, Tsuji K, Itobayashi E, Kariyama K, Ishikawa T, Tajiri K, Ochi H, Tada T, Toyoda H, Nouso K, Joko K, Kawasaki H, Hiasa Y, Michitaka K; Real-Life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics). Hiraoka A, et al. Among authors: tada t. Liver Cancer. 2017 Jun;6(3):204-215. doi: 10.1159/000452846. Epub 2017 Mar 9. Liver Cancer. 2017. PMID: 28626732 Free PMC article.
Characteristics and Prognosis of Hepatocellular Carcinoma in Japanese Patients Undergoing Dialysis.
Toyoda H, Hiraoka A, Tada T, Michitaka K, Takaguchi K, Tsuji K, Itobayashi E, Takizawa D, Hirooka M, Koizumi Y, Ochi H, Joko K, Kisaka Y, Shimizu Y, Tajiri K, Tani J, Taniguchi T, Toshimori A, Fujioka S, Kumada T. Toyoda H, et al. Among authors: tada t. Ther Apher Dial. 2017 Oct;21(5):465-472. doi: 10.1111/1744-9987.12563. Epub 2017 Sep 7. Ther Apher Dial. 2017. PMID: 28880488
Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis.
Hiraoka A, Kumada T, Kudo M, Hirooka M, Koizumi Y, Hiasa Y, Tajiri K, Toyoda H, Tada T, Ochi H, Joko K, Shimada N, Deguchi A, Ishikawa T, Imai M, Tsuji K, Michitaka K; Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics). Hiraoka A, et al. Among authors: tada t. Dig Dis. 2017;35(6):602-610. doi: 10.1159/000480256. Epub 2017 Oct 17. Dig Dis. 2017. PMID: 29040999 Clinical Trial.
Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan.
Toyoda H, Atsukawa M, Takaguchi K, Senoh T, Michitaka K, Hiraoka A, Fujioka S, Kondo C, Okubo T, Uojima H, Tada T, Yoneyama H, Watanabe T, Asano T, Ishikawa T, Tamai H, Abe H, Kato K, Tsuji K, Ogawa C, Shimada N, Iio E, Deguchi A, Itobayashi E, Mikami S, Moriya A, Okubo H, Tani J, Tsubota A, Tanaka Y, Masaki T, Iwakiri K, Kumada T. Toyoda H, et al. Among authors: tada t. J Gastroenterol. 2018 Dec;53(12):1276-1284. doi: 10.1007/s00535-018-1473-z. Epub 2018 May 8. J Gastroenterol. 2018. PMID: 29740665
Proposed a simple score for recommendation of scheduled ultrasonography surveillance for hepatocellular carcinoma after Direct Acting Antivirals: multicenter analysis.
Hiraoka A, Kumada T, Ogawa C, Kariyama K, Morita M, Nouso K, Toyoda H, Tada T, Ochi M, Murakami T, Izumoto H, Ueki H, Kitahata S, Aibiki T, Okudaira T, Yamago H, Iwasaki R, Tomida H, Miyamoto Y, Mori K, Miyata H, Tsubouchi E, Kishida M, Ninomiya T, Michitaka K. Hiraoka A, et al. Among authors: tada t. J Gastroenterol Hepatol. 2019 Feb;34(2):436-441. doi: 10.1111/jgh.14378. Epub 2018 Jul 29. J Gastroenterol Hepatol. 2019. PMID: 29996177
Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis.
Hiraoka A, Kumada T, Kariyama K, Takaguchi K, Itobayashi E, Shimada N, Tajiri K, Tsuji K, Ishikawa T, Ochi H, Hirooka M, Tsutsui A, Shibata H, Tada T, Toyoda H, Nouso K, Joko K, Hiasa Y, Michitaka K; Real-life Practice Experts for HCC (RELPEC) Study Group and the HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Hiraoka A, et al. Among authors: tada t. Hepatol Res. 2019 Jan;49(1):111-117. doi: 10.1111/hepr.13243. Epub 2018 Oct 9. Hepatol Res. 2019. PMID: 30144256
Impact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time-dependent receiver operating characteristic.
Tada T, Kumada T, Toyoda H, Tsuji K, Hiraoka A, Michitaka K, Deguchi A, Ishikawa T, Imai M, Ochi H, Joko K, Shimada N, Tajiri K, Hirooka M, Koizumi Y, Hiasa Y, Tanaka J. Tada T, et al. J Gastroenterol Hepatol. 2019 Jun;34(6):1066-1073. doi: 10.1111/jgh.14564. Epub 2019 Feb 27. J Gastroenterol Hepatol. 2019. PMID: 30549320
1,650 results